Alzheimer's Research Pioneer Bateman Wins 2026 Goodes Prize for Blood Test Breakthroughs
Event summary
- Randall J. Bateman, MD, receives the 2026 Melvin R. Goodes Prize for Alzheimer's research contributions.
- Bateman co-founded C2N Diagnostics, which developed the first FDA-approved Alzheimer's blood test, PrecivityAD.
- Next-generation PrecivityAD2 test is currently under FDA review.
- Bateman directs DIAN-TU clinical trials, redefining early intervention timelines for Alzheimer's.
The big picture
The recognition of Bateman underscores the growing importance of diagnostics and AI in Alzheimer's research. The field is shifting from late-stage treatment to early detection and prevention, with blood tests playing a pivotal role in trial enrollment and therapy evaluation. The ADDF's venture philanthropy model continues to fuel innovation, having supported nearly $394 million in Alzheimer's drug development programs globally.
What we're watching
- Diagnostic Adoption
- The pace at which next-generation Alzheimer's blood tests like PrecivityAD2 gain FDA approval and clinical adoption.
- AI Integration
- How Bateman's C-BRAIN AI initiative will accelerate pattern recognition in complex, data-rich Alzheimer's research.
- Prevention Timeline
- Whether early intervention timelines redefined by DIAN-TU trials can translate into preventable treatment strategies.
Related topics